Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Recursion Pharmaceuticals, Inc. Class A Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.79
-12% in 7d after detection
Post-detection moves
1h
—
1d
+1.5%
3d
-3.7%
7d
-12%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS